News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
716,702 Results
Type
Article (54809)
Company Profile (242)
Press Release (661651)
Multimedia
Podcasts (100)
Webinars (12)
Section
Business (200085)
Career Advice (3122)
Deals (36600)
Drug Delivery (121)
Drug Development (83912)
Employer Resources (174)
FDA (17046)
Job Trends (16067)
News (347681)
Policy (34747)
Tag
2024 BioCapital Digital (8)
2024 BioForest Digital (5)
2024 BioForest Standard (1)
2024 BioMidwest Digital (6)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (5)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (18)
2024 Biotech Beach Digital (9)
2024 Biotech Beach Standard (5)
2024 Genetown Digital (3)
2024 Genetown Standard (10)
2024 Lone Star Bio Digital (5)
2024 Pharm Country Digital (5)
2024 Pharm Country Standard (5)
2025 BioForest Digital (4)
2025 Lone Star Bio Digital (5)
2026 BioCapital Elite (1)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (2)
2026 Bio NC Standard (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (2)
2026 Genetown Elite (3)
2026 Genetown Standard (1)
2026 Pharm Country Elite (1)
2026 Pharm Country Premier (1)
2026 Pharm Country Standard (2)
Academia (2922)
Academic (1)
Accelerated approval (6)
Adcomms (29)
Allergies (91)
Alliances (50201)
ALS (99)
Alzheimer's disease (1484)
Antibody-drug conjugate (ADC) (151)
Approvals (17019)
Artificial intelligence (282)
Autoimmune disease (28)
Automation (16)
Bankruptcy (366)
Best Places to Work (12454)
BIOSECURE Act (21)
Biosimilars (118)
Biotechnology (139)
Bladder cancer (84)
Brain cancer (29)
Breast cancer (291)
Cancer (2351)
Cardiovascular disease (199)
Career advice (2624)
Career pathing (34)
CAR-T (163)
Cell therapy (457)
Cervical cancer (18)
Clinical research (68019)
Collaboration (889)
Compensation (529)
Complete response letters (29)
COVID-19 (2803)
CRISPR (45)
C-suite (253)
Cystic fibrosis (107)
Data (2189)
Decentralized trials (2)
Denatured (26)
Depression (51)
Diabetes (287)
Diagnostics (6821)
Digital health (19)
Diversity (7)
Diversity, equity & inclusion (41)
Drug discovery (128)
Drug pricing (122)
Drug shortages (32)
Duchenne muscular dystrophy (100)
Earnings (77865)
Editorial (43)
Employer branding (22)
Employer resources (152)
Events (114214)
Executive appointments (762)
FDA (18325)
Featured Employer (61)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (787)
Gene editing (114)
Generative AI (24)
Gene therapy (338)
GLP-1 (826)
Government (4858)
Grass and pollen (5)
Guidances (53)
Healthcare (20604)
Huntington's disease (25)
IgA nephropathy (30)
Immunology and inflammation (140)
Indications (29)
Infectious disease (2963)
Inflammatory bowel disease (150)
Inflation Reduction Act (9)
Influenza (55)
Intellectual property (98)
Interviews (616)
IPO (16979)
IRA (48)
Job creations (4057)
Job search strategy (2155)
Kidney cancer (11)
Labor market (34)
Layoffs (529)
Leadership (22)
Legal (8317)
Liver cancer (77)
Lung cancer (337)
Lymphoma (155)
Machine learning (6)
Management (63)
Manufacturing (331)
MASH (73)
Medical device (14331)
Medtech (14336)
Mergers & acquisitions (20177)
Metabolic disorders (757)
Multiple sclerosis (81)
NASH (23)
Neurodegenerative disease (106)
Neuropsychiatric disorders (34)
Neuroscience (2062)
NextGen: Class of 2025 (7245)
Non-profit (5003)
Northern California (2685)
Now hiring (39)
Obesity (409)
Opinion (267)
Ovarian cancer (75)
Pain (95)
Pancreatic cancer (83)
Parkinson's disease (158)
Partnered (21)
Patents (244)
Patient recruitment (109)
Peanut (50)
People (60106)
Pharmaceutical (92)
Pharmacy benefit managers (21)
Phase I (21039)
Phase II (29842)
Phase III (22543)
Pipeline (1194)
Policy (163)
Postmarket research (2779)
Preclinical (8915)
Press Release (67)
Prostate cancer (107)
Psychedelics (38)
Radiopharmaceuticals (266)
Rare diseases (420)
Real estate (6075)
Recruiting (70)
Regulatory (23824)
Reports (31)
Research institute (2604)
Resumes & cover letters (493)
Rett syndrome (4)
RNA editing (3)
RSV (47)
Schizophrenia (76)
Series A (136)
Series B (89)
Service/supplier (13)
Sickle cell disease (58)
Southern California (2322)
Special edition (18)
Spinal muscular atrophy (160)
Sponsored (31)
Startups (3662)
State (2)
Stomach cancer (15)
Supply chain (75)
Tariffs (39)
The Weekly (72)
United States (23600)
Vaccines (757)
Venture capitalists (42)
Weight loss (291)
Women's health (30)
Worklife (19)
Date
Today (201)
Last 7 days (803)
Last 30 days (2614)
Last 365 days (34758)
2025 (10770)
2024 (37206)
2023 (42301)
2022 (53642)
2021 (58369)
2020 (57228)
2019 (50702)
2018 (38448)
2017 (34819)
2016 (34198)
2015 (39649)
2014 (31535)
2013 (26493)
2012 (28144)
2011 (28703)
2010 (26132)
Location
Africa (964)
Alabama (58)
Alaska (7)
Arizona (203)
Arkansas (14)
Asia (43651)
Australia (7767)
California (6136)
Canada (2008)
China (543)
Colorado (275)
Connecticut (287)
Delaware (149)
Europe (97956)
Florida (912)
Georgia (215)
Idaho (60)
Illinois (568)
India (28)
Indiana (326)
Iowa (10)
Japan (164)
Kansas (101)
Kentucky (26)
Louisiana (10)
Maine (70)
Maryland (928)
Massachusetts (4718)
Michigan (239)
Minnesota (410)
Mississippi (2)
Missouri (90)
Montana (31)
Nebraska (25)
Nevada (65)
New Hampshire (68)
New Jersey (1757)
New Mexico (30)
New York (1752)
North Carolina (1043)
North Dakota (8)
Northern California (2685)
Ohio (210)
Oklahoma (14)
Oregon (40)
Pennsylvania (1368)
Puerto Rico (12)
Rhode Island (33)
South America (1329)
South Carolina (22)
South Dakota (1)
Southern California (2322)
Tennessee (103)
Texas (908)
Utah (188)
Virginia (158)
Washington D.C. (67)
Washington State (571)
West Virginia (3)
Wisconsin (59)
716,702 Results for "moberg pharma ab formerly known as moberg derma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Cipher Pharmaceuticals Partner Moberg Pharma AB Reports Topline Data in MOB-015 Phase 3 Study
December 10, 2024
·
7 min read
Moberg Pharma has secured exercise of warrants and entered into a top guarantee free of charge - June 11, 2024
Moberg Pharma AB has received subscription intentions, subscription commitments and top guarantee commitments totaling approximately SEK 113.5 million, related to the warrants of series 2023:1, from a few external professional investors and the Company’s largest shareholder, Östersjöstiftelsen.
June 11, 2024
·
7 min read
Moberg Pharma receives SEK 336 million through TO 2 and directed issue to top guarantors - subscription rate in TO 2 of 98%
Moberg Pharma announces that 17,776,856 warrants of series 2023:1 were exercised for subscription of in total 17,776,856 ordinary shares for approximately SEK 320 million, corresponding to a subscription rate of approximately 98%.
June 24, 2024
·
6 min read
Drug Development
Cipher Pharmaceuticals Partner Moberg Pharma AB Provides Update on MOB-015 Phase 3 Study
September 13, 2024
·
6 min read
Drug Development
Moberg Pharma has completed enrollment to the Phase 3 study for MOB-015 in North America
Moberg Pharma AB has completed the recruitment of 384 patients with onychomycosis for the ongoing MOB-015 phase 3 study in North America.
October 6, 2023
·
3 min read
Drug Development
MOB-015 is recommended for approval in EU: Moberg Pharma
Moberg Pharma AB hereby announces that the Decentralized Procedure has ended with a positive outcome and that MOB-015 is recommended for national approval in 13 European countries for the treatment of mild to moderate fungal infections of the nails in adults.
June 28, 2023
·
8 min read
Press Releases
Notice to Annual General Meeting in AlzeCure Pharma AB
April 9, 2025
·
9 min read
MOB-015 is launched in Sweden under the brand name Terclara- pharmacies report major demand for the new medication
Moberg Pharma ABs marker partner in Sweden - Allderma AB, a company which specialises in the sale of over-the-counter pharmaceuticals - has now launched sales of MOB-015 under the Terclara® brand.
February 7, 2024
·
4 min read
Press Releases
Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB
February 6, 2025
·
7 min read
Moberg Pharma and Padagis sign agreement for MOB-015 in Israel
Moberg Pharma AB has signed a distribution agreement with Padagis Israel Agencies Ltd. for MOB-015 in Israel and the Palestinian territories.
August 4, 2022
·
2 min read
1 of 71,671
Next
